Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: January 20, 2026
Context: The filing incorporates by reference a press release announcing the completion of patient enrollment in a Phase 2a clinical study for the company's drug candidate, Namodenoson, in the treatment of pancreatic cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development milestone and does not contain financial statements or quantitative financial data.
Material Changes
Clinical Progress: The primary material change is the completion of patient enrollment in the Phase 2a study of Namodenoson for pancreatic cancer. No financial changes or comparisons to prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the study enrollment but does not include specific management commentary, future financial guidance, or detailed risk factors within the body of this Form 6-K.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the full details of the Phase 2a Namodenoson study by reviewing the attached press release (Exhibit 99.1).
- Confirm the timeline for the next clinical data readout or interim results from the completed enrollment.
- Review the company's most recent Form 20-F or quarterly reports for current cash runway and burn rate, as this filing contains no financial data.
- Assess the regulatory pathway for Namodenoson in pancreatic cancer based on the Phase 2a design.